Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study

Neurology

Volumn 93, Issue 10, 2019, Pages E1010-E1020

  Douros, Antonios ^a,b   Dell'Aniello, Sophie ^a,d   Dehghan, Golsa ^a   Boivin, Jean François ^a,b   Renoux, Christel ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b Occupational Health ^*  (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; VILOXAZINE; SEROTONIN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE RISK ASSESSMENT; EFFECT SIZE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY ANALYSIS; SEROTONIN REUPTAKE; SEROTONIN UPTAKE; CEREBROVASCULAR ACCIDENT; METABOLISM; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BRAIN ISCHEMIA; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STROKE;

EID: 85071785956     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000008060     Document Type: Article

References (35)

1. Pratt LA, Brody DJ, Gu Q,. Antidepressant use among persons aged 12 and over: United States, 2011-2014.: NCHS Data Brief 2017: 1-8.
2. Hare DL, Toukhsati SR, Johansson P, Jaarsma T,. Depression and cardiovascular disease: A clinical review. Eur Heart J 2014; 35: 1365-1372.
3. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen E, Hallas J, García Rodríguez LA, Christensen K, Gaist D,. Selective serotonin reuptake inhibitors and the risk of stroke: A population-based case-control study. Stroke 2002; 33: 1465-1473.
4. Castro VM, Gallagher PJ, Clements CC, et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open 2012; 2: e000544.
5. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J,. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ 2016; 352: i1350.
6. Meier CR, Schlienger RG, Jick H,. Use of selective serotonin reuptake inhibitors and risk of developing first-Time acute myocardial infarction. Br J Clin Pharmacol 2001; 52: 179-184.
7. Sauer WH, Berlin JA, Kimmel SE,. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-1898.
8. Sauer WH, Berlin JA, Kimmel SE,. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-36.
9. Wu CS, Wang SC, Cheng YC, Gau SS,. Association of cerebrovascular events with antidepressant use: A case-crossover study. Am J Psychiatry 2011; 168: 511-521.
10. Wu CS, Wu HT, Tsai YT, Huang YW, Tsai HJ,. Use of antidepressants and risk of hospitalization for acute myocardial infarction: A nationwide case-crossover study. J Psychiatr Res 2017; 94: 7-14.
11. Schlienger RG, Meier CR,. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am J Cardiovasc Drugs 2003; 3: 149-162.
12. de Abajo FJ,. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28: 345-367.
13. de Abajo FJ, Rodríguez LA, Montero D,. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109.
14. Douros A, Ades M, Renoux C,. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: A systematic review. CNS Drugs 2018; 32: 321-334.
15. Renoux C, Vahey S, Dell'Aniello S, Boivin JF,. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol 2017; 74: 173-180.
16. Walley T, Mantgani A,. The UK General Practice Research Database. Lancet 1997; 350: 1097-1099.
17. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ,. Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
18. Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R,. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017; 356: j603.
19. NICE. Depression in adults: recognition and management [online]. Available at: nice.org.uk/guidance/cg90. Accessed July 3, 2017.
20. Hamer M, Batty GD, David Batty G, Seldenrijk A,. Antidepressant medication use and future risk of cardiovascular disease: The Scottish Health Survey. Eur Heart J 2011; 32: 437-442.
21. Kivimaki NF, Harrison SE, Rose PW,. Validity of diagnostic coding within the General Practice Research Database: A systematic review. Br J Gen Pract 2010; 60: e128-36.
22. Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 2013; 346: f2350.
23. Tatsumi M, Groshan K, Blakely RD, Richelson E,. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-258.
24. Breslow NE, Day NE, International Agency for Research on Cancer. Statistical Methods in Cancer Research: The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1988.
25. Suissa S,. Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis: Pharmacoepidemiology. New York: John Wiley & Sons, Ltd; 2002: 785-805.
26. Essebag V, Platt RW, Abrahamowicz M, Pilote L,. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5: 5.
27. Rubin DB,. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons; 2004.
28. Schafer JL,. Analysis of Incomplete Multivariate Data. Boca Raton, FL: CRC Press; 1997.
29. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA,. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-522.
30. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 3754-3832.
31. Maclure M,. The case-crossover design: A method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
32. Antithrombotic Trialists' Collaboration. Collaborative meta-Analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
33. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS,. Selection of controls in case-control studies, II: Types of controls. Am J Epidemiol 1992; 135: 1029-1041.
34. Drews C, Greenland S, Flanders WD,. The use of restricted controls to prevent recall bias in case-control studies of reproductive outcomes. Ann Epidemiol 1993; 3: 86-92.
35. Medicines and Healthcare products Regulatory Agency. Citalopram and escitalopram: QT interval prolongation [online]. Available at: gov.uk/drug-safety-update/citalopram-And-escitalopram-qt-interval-prolongation. Accessed June 28, 2018.